eftilagimod alpha,pembrolizumab
Immutep,Merck
['eftilagimod', 'immutep', '$immp']
$immp immutep announces compelling clinical results from phase ii trial utilizing its first-in-class soluble lag-3 protein, eftilagimod alpha, in 1st line nsclc at sitc 2022 annual meeting #clinicaltrial #clinicaltrial stock news alerts in bio